NASDAQ$CCCC
C4 Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
C4 Therapeutics reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights.
C4 Therapeutics reported a net loss of $34.8 million for the first quarter of 2023, with revenue of $3.8 million. The company's cash, cash equivalents, and marketable securities totaled $305.0 million as of March 31, 2023, expected to provide runway into 2025.
- Progressed three orally bioavailable degrader programs through the clinic and presented new preclinical data from CFT1946 at AACR.
- CFT7455 Phase 1/2 clinical trial continues in MM and NHL.
- CFT8634 Phase 1/2 clinical trial continues in synovial sarcoma and SMARCB1-null solid tumors.
- CFT1946 Phase 1/2 clinical trial was initiated in January and is enrolling patients with BRAF V600 solid tumors.
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$3.76M
Revenue by segment
C4 Therapeutics · $3.76M total across 1 segment · Q1 2023
- Collaboration agreements$3.76M—100.0%
Forward guidance
C4T expects that its cash, cash equivalents and marketable securities as of March 31, 2023, along with cost savings, will be sufficient to fund planned operating expenses and capital expenditures into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+24.0%
Q4 2023
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +13.0% | +22.2% | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro